Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for relieving or eliminating protracted opioid abstinence syndrome and application of pharmaceutical composition

A composition and syndrome technology, applied in the fields of addiction medicine and neurobiology, can solve the problems of long withdrawal time, poor medication compliance and medication experience of patients, and poor clinical application effect, and achieve the elimination of withdrawal symptoms, Obvious clinical advantages and curative effects, and the effect of improving medication experience

Active Publication Date: 2021-03-16
SHENZHEN SCIENCARE MEDICAL INDUSTRIES CO. LTD.
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the invention takes a long time to withdraw, the patient's medication compliance and medication experience are poor, and the clinical application effect is poor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for relieving or eliminating protracted opioid abstinence syndrome and application of pharmaceutical composition
  • Pharmaceutical composition for relieving or eliminating protracted opioid abstinence syndrome and application of pharmaceutical composition
  • Pharmaceutical composition for relieving or eliminating protracted opioid abstinence syndrome and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-3

[0037] Embodiment 1-3 A kind of compound tablet for alleviating or eliminating opioid withdrawal syndrome

[0038] Table 1 shows the prescription of a compound tablet for alleviating or eliminating the opioid withdrawal syndrome of Examples 1-3.

[0039] Table 1 A kind of prescription of compound tablet for alleviating or eliminating opioid withdrawal syndrome (each tablet contains / mg)

[0040]

[0041]

Embodiment 4-10

[0042] Embodiment 4-10 A kind of compound tablet for alleviating or eliminating opioid withdrawal syndrome

[0043] Table 2 shows the prescription of a compound tablet for alleviating or eliminating the opioid withdrawal syndrome of Examples 4-10.

[0044] Table 2 A kind of prescription of compound tablet for alleviating or eliminating opioid withdrawal syndrome (each tablet contains / mg)

[0045]

[0046] The preparation method of the compound tablet comprises the following steps:

[0047] (1) the clonidine hydrochloride of recipe quantity is dissolved in water, sieve after granulation with recipe quantity microcrystalline cellulose, oven dry, obtain granule;

[0048] (2) the granule obtained in step (1) is mixed with the tramadol hydrochloride and lactose monohydrate of recipe quantity, then silicon dioxide and the magnesium stearate of recipe quantity are added and mixed, and the coating is compressed into a tablet, to obtain the The compound tablet.

experiment example 2

[0086] Experimental example 2. The main pharmacodynamics study of drugs inhibiting morphine withdrawal symptoms

[0087] (1) Mouse jumping test

[0088] The mice were randomly divided into blank control group and drug group 1-12 by body weight, wherein, drug group 1-12 (respectively administered compound tablets prepared in Example 1-10 and single tablets prepared in Comparative Example 1-2), Divided into low-dose group, middle-dose group and high-dose group, 10 in each group. All groups were intraperitoneally injected with morphine, 6 times a day, with a dose of 10 mg / kg / time on the first day, 10 mg / kg / time on the 2nd-3rd day, 50 minutes after the last injection of morphine, the low-dose group of the drug , middle-dose group and high-dose group were administered by intragastric administration of 36 mg / kg, 72 mg / kg and 143 mg / kg respectively, and the blank control group was administered an equal volume of normal saline. After 30 minutes of intragastric administration, each gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for relieving or eliminating protracted opioid abstinence syndrome and application of the pharmaceutical composition. The pharmaceutical composition comprises clonidine hydrochloride and tramadol hydrochloride in a mass ratio of (0.01-0.8):(40-60), and the application of the pharmaceutical composition in preparation of drugs for relieving or eliminating the protracted opioid abstinence syndrome is also disclosed. The pharmaceutical composition is more suitable for detoxification of opioid abuse patients, has the advantages of good effect, short time, completion in 3-5 days, safety, effectiveness and convenience in operation, has obvious clinical advantages and curative effects, can improve the medication compliance and medication experience of the patients, and prevents abuse.

Description

technical field [0001] The invention relates to the technical fields of addiction medicine and neurobiology, in particular to a pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome. Background technique [0002] Drug abuse addiction has become a public hazard in the world. It not only endangers the physical and mental health of addicts, but also seriously interferes with social security and the development of productivity. At present, comprehensive medical, psychological and social measures are recommended for the treatment of opioid dependence, including stopping drug abuse, detoxification treatment for withdrawal symptoms, and rehabilitation and prevention of psychological dependence and other physical, psychological, and social functional impairments. drug addiction treatment, and ultimately realize the rehabilitation and social reintegration of drug addicts. During treatment, the severity of drug dependence should be first...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4168A61K31/137A61K9/28A61K47/38A61K47/26A61K47/04A61P25/36
CPCA61K31/4168A61K31/137A61K9/2054A61K9/2009A61K9/2018A61K9/28A61P25/36A61K2300/00A61K31/135A61K9/2013A61K9/2095A61K9/2893
Inventor 梁铮林尹述贵颜携国王实强张涛
Owner SHENZHEN SCIENCARE MEDICAL INDUSTRIES CO. LTD.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com